HSD3B1 and Response to a Nonsteroidal CYP17A1 Inhibitor in Castration-Resistant Prostate Cancer

Overview of attention for article published in JAMA Oncology, April 2018

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (95th percentile)
Above-average Attention Score compared to outputs of the same age and source (58th percentile)

Mentioned by

news: 2 news outlets
twitter: 66 X users

facebook: 3 Facebook pages
googleplus: 1 Google+ user

Readers on

mendeley: 52 Mendeley

So far, Altmetric has seen 80 X posts from 66 X users, with an upper bound of 406,961 followers.

https://t.co/eR18Ri6te5

RT @NimaSharifiMD: Fourth, data w/ #abiraterone mirror our data with CYP17A1 inhib with keto in our 2018 @NimaAlmassi @reichard_chad @JAMAO…

Fourth, data w/ #abiraterone mirror our data with CYP17A1 inhib with keto in our 2018 @NimaAlmassi @reichard_chad @JAMAOnc paper. Together, HSD3B1 variant = worse outcomes w/ ADT and better outcomes w/ CYP17A1 inhib = predictive not prognostic #biomark…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 76 additional X posts.